Wire open Last filed CagriSema bone density data at ObesityWeek point to a calcitonin receptor role RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire
RoutineSAFNews

Karl Stefanovic Ozempic comments draw caution on weight and medical need

The TV host says he lost 15 kg on Ozempic and called use by people at 65 to 80 kg an ego trip. A sports nutritionist says weight alone cannot decide who should take the drug.

Editorial illustration for the story: Karl Stefanovic Ozempic comments draw caution on weight and medical need
Illustration: Peptide Zone. Editorial drawing, not data.

What's new

Karl Stefanovic said on his podcast that he lost 15 kg on Ozempic and called use by people at 65 to 80 kg an ego trip; a sports nutritionist replied that weight alone cannot decide medical need.

Why it matters

In Australia Ozempic is registered for type 2 diabetes, so weight loss use is off label, and compounded copies have been banned since October 2024.

What's next

Prescribing decisions stay with doctors and TGA rules; readers considering treatment should seek a full medical assessment.

Karl Stefanovic Ozempic remarks on his own podcast have drawn a response from a sports nutritionist who says body weight alone cannot decide who should use the drug. The Australian television host, 52, said he lost 15 kg on Ozempic after starting at 105 kg, then questioned its use by people who weigh between 65 and 80 kg. New Idea published the nutritionist's reply on 16 November, after Stefanovic discussed the drug with personal trainer James Smith.

What Karl Stefanovic said on his podcast

Stefanovic first spoke about his weight loss in May, when he told listeners of The Karl Stefanovic Show that he had lost 15 kg with the help of a GLP 1 medicine. He said he had been exercising regularly but could not shift the weight, and that a doctor had told him he was unhealthy. In the latest episode, recorded with Smith, a coach who built a large weight loss business, he named the drug as Ozempic and said it took him from 105 kg. He described the earlier struggle as "upsetting and frustrating". He has since stopped the medicine, according to both magazine reports on the episode, and says he keeps the weight off with gym sessions and walks.

The comments that drew attention came next. Stefanovic said that "half of his friends" had used the drug, and he wrote on Instagram that the chat with Smith "has opened my eyes". He said the medicines help people who are overweight or obese, but added: "if you're 65kg or 75kg or 80kg then it's just an ego trip, isn't it?" He also said something about that use "doesn't sit right" with him. New Idea reported that he raised these points while discussing Australians who buy cheap, unapproved weight loss products. None of the reports gives medical details of his own treatment, such as the prescriber's reasons or how long he took it.

Why weight alone does not settle medical need

Lucinda Porcelli, a former paramedic and sports nutritionist, told New Idea that she agreed with part of his message. "I agree with Karl's broader message that Ozempic and other GLP-1 medications can have significant benefits when prescribed appropriately," she said. Her disagreement was with the weight cut off. A person who weighs 70 or 80 kg may still have a real medical reason for treatment, she said, depending on height, health conditions and a full clinical assessment. That point matches how these drugs are judged in practice: a doctor looks at body size in relation to height and at linked conditions, not at a number on the scale. A short adult at 75 kg and a tall adult at 75 kg can sit in very different health risk groups.

A short adult at 75 kg and a tall adult at 75 kg can sit in very different health risk groups.

Porcelli did share his worry about cosmetic use. She said she was concerned about healthy people taking the drugs "purely for cosmetic weight loss" to drop a few kilograms. She also warned that the medicine does not teach eating skills, which can lead to regain after people stop. Strong appetite loss can leave people short of energy, protein and other nutrients, she said, "potentially compromising muscle mass, recovery and overall health." Her view was that the drugs belong in care only when medically appropriate and with nutrition support. Those concerns echo questions raised in our report on long term GLP 1 effects, where the evidence on lasting harms remains thin.

How Ozempic is regulated in Australia

In Australia, Ozempic is registered with the Therapeutic Goods Administration for type 2 diabetes, so prescribing it for weight loss is off label. The TGA approved a separate semaglutide product, Wegovy, for weight management. During the Ozempic shortage that began in 2022, the TGA strongly recommended that supply go to patients with registered uses, and it advised doctors to avoid starting new patients, RACGP newsGP reported in February 2023. That history is one reason the Karl Stefanovic Ozempic story landed with doctors and dietitians. The drug he named is a diabetes medicine, and its use for weight loss outside the approved indication was a large part of what drove the shortage, according to the regulator's guidance at the time.

The government went further with copies of these drugs. From 1 October 2024, compounded GLP 1 receptor agonists such as semaglutide and tirzepatide were removed from the pharmacy compounding exemption. The health department said compounded versions are not identical to the approved products, have not been assessed by the TGA for safety or efficacy, and were being made at a scale closer to commercial manufacture, Australian Pharmacist reported. The government estimated that about 20,000 people were using compounded versions at the time, mostly for off label weight loss. Products sold outside the pharmacy system carry more risk again, as shown in a case of liver failure after an unapproved vial of another drug.

DateEventSource
February 2023TGA urges priority supply of Ozempic for type 2 diabetesRACGP newsGP
1 October 2024Compounded GLP 1 drugs removed from the compounding exemptionAustralian Pharmacist
May 2026Stefanovic says he lost 15 kg with a GLP 1 drugNow To Love
16 November 2026Nutritionist says weight alone cannot decide medical needNew Idea

What the celebrity debate leaves out

The Karl Stefanovic Ozempic episode shows how public figures who talk about these drugs shape how people see them. Stefanovic's account gives a familiar picture: a man who was active, could not lose weight, saw a doctor and was offered a medicine. His remark about people at lower weights touches a real clinical concern about cosmetic use, but a weight range is a blunt way to judge it. Approved weight management products are prescribed against criteria that combine body mass index with weight related conditions. Off label use, compounded copies and unapproved products sit outside those checks, and that is where regulators have focused. None of this is visible in a podcast clip, which is why the clinical detail matters more than the headline figure.

For readers, the practical point is simple. Whether a GLP 1 medicine is right for someone depends on a medical assessment, not on a celebrity's experience or a weight cut off quoted in an interview. People who stop treatment may regain weight unless eating and activity habits change, and Porcelli's warning about nutrition and muscle reflects that. Unapproved or compounded copies bought outside the pharmacy system carry risks that the approved products do not. The Peptide Zone safety desk tracks regulator warnings, side effect reviews and the unapproved market. This story is research and news only and is not medical advice for any person.

Conclusion

The Karl Stefanovic Ozempic comments turned a personal story into a debate about who should use weight loss drugs. His concern about cosmetic use has support, but a sports nutritionist and the way regulators frame these medicines both point the same way: medical need depends on a full assessment, not on weight alone. In Australia, Ozempic remains a diabetes medicine, Wegovy is the approved weight product, and compounded copies have been off the table since October 2024.

More from the wire

Same thread first, then the same desk.